National Cancer Institute; Notice of Meeting, 26303-26304 [2012-10699]
Download as PDF
<![CDATA[
wreier-aviles on DSK7SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 86 / Thursday, May 3, 2012 / Notices
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Bahiru Gametchu, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204,
MSC 7812, Bethesda, MD 20892, 301–408–
9329, gametchb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA RM11–
006: Transformative R01 Roadmap Review.
Date: May 31, 2012.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: John L. Bowers, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4170,
MSC 7806, Bethesda, MD 20892, (301) 435–
1725, bowersj@csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Molecular and
Integrative Signal Transduction Study
Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Alexandria, 480 King
Street, Alexandria, VA 22314.
Contact Person: Raya Mandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5134,
MSC 7840, Bethesda, MD 20892, (301) 402–
8228, rayam@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Kidney, Nutrition, Obesity and Diabetes
Study Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Delfina Santa Monica
Hotel, 530 West Pico Boulevard, Santa
Monica, CA 90405.
Contact Person: Fungai Chanetsa, Ph.D.,
MPH, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3135,
MSC 7770, Bethesda, MD 20892, 301–408–
9436, fungai.chanetsa@nih.hhs.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Molecular and Cellular Hematology Study
Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Luis Espinoza, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6183,
MSC 7804, Bethesda, MD 20892, 301–495–
1213, espinozala@mail.nih.gov.
VerDate Mar<15>2010
15:32 May 02, 2012
Jkt 226001
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Psychosocial Development, Risk and
Prevention Study Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sax Chicago, 333 N. Dearborn,
Chicago, IL 60654.
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review, Group;
Neuroendocrinology, Neuroimmunology,
Rhythms and Sleep Study Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Pier 5 Hotel, 711 Eastern Avenue,
Baltimore, MD 21202.
Contact Person: Michael Selmanoff, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164,
MSC 7844, Bethesda, MD 20892, 301–435–
1119, mselmanoff@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA RM11–
006: Transformative R01 Roadmap Review.
Date: May 31, 2012.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: John L. Bowers, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4170,
MSC 7806, Bethesda, MD 20892, (301) 435–
1725, bowersj@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Drug Discovery and Molecular
Pharmacology Study Section.
Date: May 31–June 1, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Dupont Hotel, 1500 New
Hampshire Avenue NW., Washington, DC
20036.
Contact Person: Jeffrey Smiley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6194,
MSC 7804, Bethesda, MD 20892, 301–594–
7945, smileyja@csr.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Virology—-B Study Section.
Date: May 31–June 1, 2012.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Lorien Hotel and Spa, 1600 King
Street, Alexandria, VA 22314.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
26303
Contact Person: John C Pugh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1206,
MSC 7808, Bethesda, MD 20892, (301) 435–
2398, pughjohn@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–10701 Filed 5–2–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Clinical Trials
and Translational Research Advisory
Committee.
The meeting will be open to the
public, with attendance limited to pace
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: July 11, 2012.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical Trials and Translational Research
Programs.
Place: National Institutes of Health,
Building 31, C–Wing, 6th Floor, 31 Center
Drive, Conference Room 10, Bethesda, MD
20892.
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes
of Health, 6120 Executive Blvd., 3rd Floor
Suite, Bethesda, MD 20892, 301–451–5048,
prindivs@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
E:\FR\FM\03MYN1.SGM
03MYN1
26304
Federal Register / Vol. 77, No. 86 / Thursday, May 3, 2012 / Notices
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit. Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–10699 Filed 5–2–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Ocular
Therapeutics Utilizing the Peptide
C16Y and Related Peptides
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
Patent application number
Country
wreier-aviles on DSK7SPTVN1PROD with NOTICES
PCT/US2004/04142 ..................................................................................
10/588,884 ................................................................................................
2004317159 ..............................................................................................
2,555,792 ..................................................................................................
04 710659.6 ..............................................................................................
The patent rights in these inventions
have been assigned to the United States
of America.
The prospective exclusive license
territory may be ‘‘worldwide’’, and the
field of use may be limited to ‘‘use of
C16Y and related peptides in the
treatment of ocular disease.’’
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before May
18, 2012 will be considered.
FOR FURTHER INFORMATION CONTACT:
Requests for copies of the patent
application(s), inquiries, AND
comments relating to the contemplated
exclusive license should be directed to:
Susan S. Rucker, JD, CLP, Senior
Advisor for Intellectual Property
Transactions, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4478; Facsimile: (301) 402–
0220; Email: ruckersu@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
technology encompassed by the patents
and/or patent applications (IP) to be
included in this exclusive license
relates to a protein designated C16Y and
variations thereof. C16Y is an
engineered peptide derived from
laminin gamma 1 chain having antiangiogenic properties. The C16Y
peptide is at least 5-fold more potent
VerDate Mar<15>2010
15:32 May 02, 2012
Jkt 226001
PCT
US
AU
CA
EP
Filing date or
international
filing date
02/12/2004
08/09/2006
02/12/2004
2/12/2004
2/12/2004
than the previously described C16S
peptide and has been shown to inhibit
choroidal neovascularization (CNV) in
vivo and inhibit angiogenesis in a tumor
bearing mouse model (see Ponce, et al
Cancer Research 63: 5060–64 (2003)).
The IP covers various C16Y
compositions and uses thereof,
particularly its use in treating ocular
diseases.
The prospective start up exclusive
license will be royalty bearing and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective start up exclusive license
may be granted unless within fifteen
(15) days from the date of this published
notice, the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Only applications for a license in the
field of use set forth in this notice and
filed in response to this notice will be
treated as objections to the grant of the
contemplated start up exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to ODIN Biotech, a Texas
corporation, having a place of business
in Dallas, Texas, to practice the
inventions embodied in the patents and
patent applications belonging to the
patent family having HHS Reference
Number E–008–2004/0. The exclusive
license is one which qualifies under the
Start-Up License Agreement program
which is in place from October 1, 2011
through September 30, 2012. Specific
details regarding the individual patents
or patent applications which belong to
this patent family are set forth in the
table below:
SUMMARY:
Status
Expired ...............
Issued .................
Issued .................
Pending ..............
Pending ..............
Publication or patent
number
WO 2005/087250
8,039,585 B2
2004317159 B2
2555792 A1
1737479 A1
Dated: April 27, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2012–10636 Filed 5–2–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket Number FR–5623–N–01]
Federal Housing Administration (FHA)
Healthcare Facility Documents:
Proposed Revisions and Updates and
Notice of Information Collection
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Notice.
AGENCY:
Consistent with the
Paperwork Reduction Act of 1995
(PRA), HUD is publishing for public
comment a comprehensive set of closing
and other documents used in
connection with transactions involving
healthcare facilities (excluding
hospitals) that are insured pursuant to
section 232 of the National Housing Act
(Section 232). In addition to meeting
PRA requirements, this notice seeks
public comment for the purpose of
enlisting input from the lending
SUMMARY:
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 77, Number 86 (Thursday, May 3, 2012)]
[Notices]
[Pages 26303-26304]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10699]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Clinical Trials and Translational Research
Advisory Committee.
The meeting will be open to the public, with attendance limited to
pace available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: July 11, 2012.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI's Clinical Trials and
Translational Research Programs.
Place: National Institutes of Health, Building 31, C-Wing, 6th
Floor, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD, MPH, Director,
Coordinating Center for Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes of Health, 6120
Executive Blvd., 3rd Floor Suite, Bethesda, MD 20892, 301-451-5048,
prindivs@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
[[Page 26304]]
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit. Information is also available on the Institute's/Center's
home page: https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where
an agenda and any additional information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: April 27, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-10699 Filed 5-2-12; 8:45 am]
BILLING CODE 4140-01-P
